Cytokinetics, Inc. — Q3 2017 Form 10-Q
Business context and reporting period
Late-stage biopharmaceutical company developing muscle-function therapies; it had no commercial drug sales. This unaudited report covers the quarter and nine months ended September 30, 2017. Key programs were tirasemtiv for ALS, CK-2127107 for muscle-weakness indications, and omecamtiv mecarbil for heart failure.
Financial performance and position
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Revenue | $6.2m | $59.0m | $13.4m | $73.3m |
| R&D expense | $24.9m | $17.9m | $64.0m | $41.1m |
| G&A expense | $9.7m | $7.2m | $26.2m | $21.1m |
| Operating income (loss) | $(28.4)m | $34.0m | $(76.9)m | $11.0m |
| Net income (loss) | $(32.4)m | $33.4m | $(87.3)m | $9.3m |
| Operating cash flow | Not provided quarterly | Not provided quarterly | $(77.7)m | $(40.8)m |
At September 30, cash and cash equivalents were $116.3m, short-term investments $191.2m, and long-term investments $0.6m: $308.2m combined. Working capital was $279.6m. Total assets were $326.3m and stockholders’ equity $147.0m. Debt carrying value was $30.3m ($9.8m current); the future-royalty liability was $100.6m. No income-tax benefit or provision was recorded. Profit margins are not meaningful in this loss-making, pre-commercial business.
Nine-month investing cash use was $96.6m, largely reflecting net investment purchases; financing provided $223.7m. The company raised funds through equity offerings and warrant exercises, and received net proceeds of $90.6m from the royalty transaction. Common shares outstanding rose to 53.9m from 40.6m at year-end 2016.
Material changes versus the prior comparable period
- Revenue fell sharply: 2016 included recognition of a $50m Astellas upfront license fee. Q3 2017 included a $10m Amgen development milestone, partly offset by the company’s Amgen co-investment payments.
- Nine-month 2017 revenue included $13.8m of payments toward the $40m omecamtiv mecarbil Phase 3 co-investment; these were recorded as reductions to R&D revenue. Management said the co-investment may earn up to 4% incremental royalties outside Japan and provides specified co-promotion rights.
- Higher clinical and personnel costs drove R&D expense increases, particularly in skeletal-muscle programs. G&A also increased, including commercial-readiness costs. The company swung from prior-year profit to substantial losses.
- Cash and investments rose substantially, supported by equity issuance and royalty monetization, while operating cash use increased. The royalty financing created a liability and significant non-cash interest expense.
Outlook, commentary, and risks
- Management expected R&D spending to continue increasing in 2017 and G&A to increase significantly versus 2016. It expected to continue tirasemtiv Phase 3 work, CK-2127107 development with Astellas, and omecamtiv mecarbil Phase 3 development with Amgen.
- The company expected VITALITY-ALS results in Q4 2017; dosing was completed in August. It anticipated completing CK-2127107 SMA trial enrollment in 2017 and reporting data in Q1 2018. These were forward-looking expectations, not results reported in this filing.
- Management’s liquidity horizon is inconsistent within the filing: the financial-statement note says existing cash and investments should cover requirements for at least 12 months from filing, while MD&A says at least 24 months. Both statements are subject to assumptions and funding needs.
- In October 2017, after quarter-end, the company amended its loan: it drew $32m, repaid the prior $30m debt and accrued final fee, and obtained interest-only payments through May 2019 followed by 41 months of principal and interest. Additional draws of $8m and $10m are conditional on specified clinical outcomes.
- Key risks include clinical-trial failure or delay, uncertainty that regulators will accept tirasemtiv respiratory-function endpoints, dependence on Amgen and Astellas decisions and funding, need for additional capital, and no history of product-sale revenue. The company also bears co-investment and debt obligations. It reported no legal proceedings and no material change in internal financial controls; disclosure controls were assessed as effective.
Important facts for investors to verify
- Reconcile the 12-month versus 24-month liquidity statements and assess cash runway against planned trial spending and contractual commitments.
- Track VITALITY-ALS results and regulatory feedback on endpoint adequacy, as well as the CK-2127107 SMA enrollment and data timeline.
- Review the October debt amendment’s interest rate, repayment schedule, conditional borrowing availability, and associated covenants.
- Assess the royalty-sale economics, estimated future payments, and sensitivity of the $100.6m liability and non-cash interest to royalty forecasts.
- Monitor further equity issuance, share dilution, collaboration milestones, partner decisions, and the timing and accounting effects of adopting the new revenue-recognition standard in 2018.